Pair ID,Drug_A,Drug_B,MW_A,LogP_A,HBD_A,HBA_A,TPSA_A,MW_B,LogP_B,HBD_B,HBA_B,TPSA_B,Avg_MW,Avg_LogP,Sum_HBD,Sum_HBA,Avg_TPSA,raw_cluster,Cluster,Route_Prediction,MBA_Strategy
1,Methotrexate,Cyclophosphamide,45.44,-1.85,5,12,211.0,261.08,0.63,1,4,41.6,153.26,-0.6100000000000001,6,16,126.3,0,2,Route: Standard IV Infusion,Target: Clinical setting. MBA: Stable revenue through doctor 'Buy-and-Bill' model.
2,Methotrexate,Vinblastine,45.44,-1.85,5,12,211.0,811.0,3.7,3,12,154.0,428.22,0.925,8,24,182.5,2,3,Route: SC / IM Injection,Target: Long-acting release. MBA: Lifecycle management to extend patent life.
3,Methotrexate,5-FU,45.44,-1.85,5,12,211.0,130.08,-89.0,2,3,58.2,87.76,-45.425,7,15,134.6,4,0,Route: Specialized IV/Salts,Target: Rapid absorption. MBA: Focus on Acute Care/Hospital setting.
4,Methotrexate,Doxorubicin hydrochloride,45.44,-1.85,5,12,211.0,543.5,1.27,6,12,206.0,294.47,-0.29,11,24,208.5,2,3,Route: SC / IM Injection,Target: Long-acting release. MBA: Lifecycle management to extend patent life.
6,Methotrexate,Goserelin,45.44,-1.85,5,12,211.0,1269.4,-2.0,17,16,496.0,657.4200000000001,-1.925,22,28,353.5,1,4,Route: Complex Chemotherapy IV,Target: Specialized Oncology Centers. MBA: High barrier to entry for generics.
7,Methotrexate,Paclitaxel,45.44,-1.85,5,12,211.0,853.9,3.0,4,14,221.0,449.67,0.575,9,26,216.0,2,3,Route: SC / IM Injection,Target: Long-acting release. MBA: Lifecycle management to extend patent life.
8,Methotrexate,Anastrozole,45.44,-1.85,5,12,211.0,293.4,1.58,0,4,78.3,169.42,-0.135,5,16,144.65,0,2,Route: Standard IV Infusion,Target: Clinical setting. MBA: Stable revenue through doctor 'Buy-and-Bill' model.
9,Methotrexate,Gemcitabine,45.44,-1.85,5,12,211.0,1269.4,-2.0,17,16,496.0,657.4200000000001,-1.925,22,28,353.5,1,4,Route: Complex Chemotherapy IV,Target: Specialized Oncology Centers. MBA: High barrier to entry for generics.
10,Methotrexate,Docetaxel,45.44,-1.85,5,12,211.0,807.9,2.4,5,14,224.0,426.67,0.2749999999999999,10,26,217.5,2,3,Route: SC / IM Injection,Target: Long-acting release. MBA: Lifecycle management to extend patent life.
11,Methotrexate,Letrozole,45.44,-1.85,5,12,211.0,285.3,2.5,0,4,78.3,165.37,0.325,5,16,144.65,0,2,Route: Standard IV Infusion,Target: Clinical setting. MBA: Stable revenue through doctor 'Buy-and-Bill' model.
12,Methotrexate,Capecitabine,45.44,-1.85,5,12,211.0,359.35,0.4,7,7,121.0,202.395,-0.7250000000000001,12,19,166.0,0,2,Route: Standard IV Infusion,Target: Clinical setting. MBA: Stable revenue through doctor 'Buy-and-Bill' model.
13,Methotrexate,Exemestane,45.44,-1.85,5,12,211.0,296.4,3.7,0,2,34.1,170.92,0.925,5,14,122.55,0,2,Route: Standard IV Infusion,Target: Clinical setting. MBA: Stable revenue through doctor 'Buy-and-Bill' model.
14,Methotrexate,Fulvestrant,45.44,-1.85,5,12,211.0,606.8,8.9,2,9,76.7,326.12,3.525,7,21,143.85,0,2,Route: Standard IV Infusion,Target: Clinical setting. MBA: Stable revenue through doctor 'Buy-and-Bill' model.
15,Methotrexate,Lapatinib,45.44,-1.85,5,12,211.0,581.1,5.4,2,9,115.0,313.27,1.775,7,21,163.0,0,2,Route: Standard IV Infusion,Target: Clinical setting. MBA: Stable revenue through doctor 'Buy-and-Bill' model.
16,Methotrexate,Palbociclib,45.44,-1.85,5,12,211.0,447.5,0.99,2,8,103.0,246.47,-0.43,7,20,157.0,0,2,Route: Standard IV Infusion,Target: Clinical setting. MBA: Stable revenue through doctor 'Buy-and-Bill' model.
17,Methotrexate,Tucatinib,45.44,-1.85,5,12,211.0,480.5,3.62,2,8,111.0,262.97,0.885,7,20,161.0,0,2,Route: Standard IV Infusion,Target: Clinical setting. MBA: Stable revenue through doctor 'Buy-and-Bill' model.
18,Methotrexate,Epirubicin,45.44,-1.85,5,12,211.0,543.5,-0.5,6,12,206.0,294.47,-1.175,11,24,208.5,2,3,Route: SC / IM Injection,Target: Long-acting release. MBA: Lifecycle management to extend patent life.
19,Methotrexate,Megestrol acetate,45.44,-1.85,5,12,211.0,384.5,3.2,0,4,60.4,214.97,0.675,5,16,135.7,0,2,Route: Standard IV Infusion,Target: Clinical setting. MBA: Stable revenue through doctor 'Buy-and-Bill' model.
20,Methotrexate,Toremifene,45.44,-1.85,5,12,211.0,406.0,6.8,0,2,12.5,225.72,2.475,5,14,111.75,0,2,Route: Standard IV Infusion,Target: Clinical setting. MBA: Stable revenue through doctor 'Buy-and-Bill' model.
21,Methotrexate,Fluoxymesterone,45.44,-1.85,5,12,211.0,336.4,2.38,2,4,57.5,190.92,0.2649999999999999,7,16,134.25,0,2,Route: Standard IV Infusion,Target: Clinical setting. MBA: Stable revenue through doctor 'Buy-and-Bill' model.
22,Methotrexate,Thiotepa,45.44,-1.85,5,12,211.0,189.22,0.53,4,3,41.1,117.33,-0.66,9,15,126.05,0,2,Route: Standard IV Infusion,Target: Clinical setting. MBA: Stable revenue through doctor 'Buy-and-Bill' model.
23,Methotrexate,methyltestosterone,45.44,-1.85,5,12,211.0,302.5,3.36,1,2,37.3,173.97,0.7549999999999999,6,14,124.15,0,2,Route: Standard IV Infusion,Target: Clinical setting. MBA: Stable revenue through doctor 'Buy-and-Bill' model.
24,Methotrexate,Pamidronate,45.44,-1.85,5,12,211.0,235.07,-4.7,6,8,161.0,140.255,-3.275,11,20,186.0,0,2,Route: Standard IV Infusion,Target: Clinical setting. MBA: Stable revenue through doctor 'Buy-and-Bill' model.
25,Cyclophosphamide,Vinblastine,261.08,0.63,1,4,41.6,811.0,3.7,3,12,154.0,536.04,2.165,4,16,97.8,0,2,Route: Standard IV Infusion,Target: Clinical setting. MBA: Stable revenue through doctor 'Buy-and-Bill' model.
26,Cyclophosphamide,5-FU,261.08,0.63,1,4,41.6,130.08,-89.0,2,3,58.2,195.58,-44.185,3,7,49.90000000000001,4,0,Route: Specialized IV/Salts,Target: Rapid absorption. MBA: Focus on Acute Care/Hospital setting.
27,Cyclophosphamide,Doxorubicin hydrochloride,261.08,0.63,1,4,41.6,543.5,1.27,6,12,206.0,402.29,0.95,7,16,123.8,0,2,Route: Standard IV Infusion,Target: Clinical setting. MBA: Stable revenue through doctor 'Buy-and-Bill' model.
28,Cyclophosphamide,Goserelin,261.08,0.63,1,4,41.6,1269.4,-2.0,17,16,496.0,765.24,-0.685,18,20,268.8,1,4,Route: Complex Chemotherapy IV,Target: Specialized Oncology Centers. MBA: High barrier to entry for generics.
29,Cyclophosphamide,Paclitaxel,261.08,0.63,1,4,41.6,853.9,3.0,4,14,221.0,557.49,1.815,5,18,131.3,0,2,Route: Standard IV Infusion,Target: Clinical setting. MBA: Stable revenue through doctor 'Buy-and-Bill' model.
30,Cyclophosphamide,Anastrozole,261.08,0.63,1,4,41.6,293.4,1.58,0,4,78.3,277.24,1.105,1,8,59.95,3,1,Route: Oral (Pill/Capsule),Target: Home-based care. MBA: High valuation for patient convenience (FDC potential).
31,Cyclophosphamide,Gemcitabine,261.08,0.63,1,4,41.6,1269.4,-2.0,17,16,496.0,765.24,-0.685,18,20,268.8,1,4,Route: Complex Chemotherapy IV,Target: Specialized Oncology Centers. MBA: High barrier to entry for generics.
32,Cyclophosphamide,Docetaxel,261.08,0.63,1,4,41.6,807.9,2.4,5,14,224.0,534.49,1.515,6,18,132.8,0,2,Route: Standard IV Infusion,Target: Clinical setting. MBA: Stable revenue through doctor 'Buy-and-Bill' model.
33,Cyclophosphamide,Letrozole,261.08,0.63,1,4,41.6,285.3,2.5,0,4,78.3,273.19,1.565,1,8,59.95,3,1,Route: Oral (Pill/Capsule),Target: Home-based care. MBA: High valuation for patient convenience (FDC potential).
34,Cyclophosphamide,Capecitabine,261.08,0.63,1,4,41.6,359.35,0.4,7,7,121.0,310.215,0.515,8,11,81.3,3,1,Route: Oral (Pill/Capsule),Target: Home-based care. MBA: High valuation for patient convenience (FDC potential).
35,Cyclophosphamide,Exemestane,261.08,0.63,1,4,41.6,296.4,3.7,0,2,34.1,278.74,2.165,1,6,37.85,3,1,Route: Oral (Pill/Capsule),Target: Home-based care. MBA: High valuation for patient convenience (FDC potential).
36,Cyclophosphamide,Fulvestrant,261.08,0.63,1,4,41.6,606.8,8.9,2,9,76.7,433.9399999999999,4.765000000000001,3,13,59.15000000000001,3,1,Route: Oral (Pill/Capsule),Target: Home-based care. MBA: High valuation for patient convenience (FDC potential).
37,Cyclophosphamide,Lapatinib,261.08,0.63,1,4,41.6,581.1,5.4,2,9,115.0,421.09,3.015,3,13,78.3,3,1,Route: Oral (Pill/Capsule),Target: Home-based care. MBA: High valuation for patient convenience (FDC potential).
38,Cyclophosphamide,Palbociclib,261.08,0.63,1,4,41.6,447.5,0.99,2,8,103.0,354.29,0.81,3,12,72.3,3,1,Route: Oral (Pill/Capsule),Target: Home-based care. MBA: High valuation for patient convenience (FDC potential).
39,Cyclophosphamide,Tucatinib,261.08,0.63,1,4,41.6,480.5,3.62,2,8,111.0,370.79,2.125,3,12,76.3,3,1,Route: Oral (Pill/Capsule),Target: Home-based care. MBA: High valuation for patient convenience (FDC potential).
40,Cyclophosphamide,Epirubicin,261.08,0.63,1,4,41.6,543.5,-0.5,6,12,206.0,402.29,0.065,7,16,123.8,0,2,Route: Standard IV Infusion,Target: Clinical setting. MBA: Stable revenue through doctor 'Buy-and-Bill' model.
41,Cyclophosphamide,Megestrol acetate,261.08,0.63,1,4,41.6,384.5,3.2,0,4,60.4,322.79,1.915,1,8,51.0,3,1,Route: Oral (Pill/Capsule),Target: Home-based care. MBA: High valuation for patient convenience (FDC potential).
42,Cyclophosphamide,Toremifene,261.08,0.63,1,4,41.6,406.0,6.8,0,2,12.5,333.54,3.715,1,6,27.05,3,1,Route: Oral (Pill/Capsule),Target: Home-based care. MBA: High valuation for patient convenience (FDC potential).
43,Cyclophosphamide,Fluoxymesterone,261.08,0.63,1,4,41.6,336.4,2.38,2,4,57.5,298.74,1.505,3,8,49.55,3,1,Route: Oral (Pill/Capsule),Target: Home-based care. MBA: High valuation for patient convenience (FDC potential).
44,Cyclophosphamide,Thiotepa,261.08,0.63,1,4,41.6,189.22,0.53,4,3,41.1,225.15,0.5800000000000001,5,7,41.35,3,1,Route: Oral (Pill/Capsule),Target: Home-based care. MBA: High valuation for patient convenience (FDC potential).
45,Cyclophosphamide,methyltestosterone,261.08,0.63,1,4,41.6,302.5,3.36,1,2,37.3,281.79,1.995,2,6,39.45,3,1,Route: Oral (Pill/Capsule),Target: Home-based care. MBA: High valuation for patient convenience (FDC potential).
46,Cyclophosphamide,Pamidronate,261.08,0.63,1,4,41.6,235.07,-4.7,6,8,161.0,248.075,-2.035,7,12,101.3,0,2,Route: Standard IV Infusion,Target: Clinical setting. MBA: Stable revenue through doctor 'Buy-and-Bill' model.
47,Vinblastine,5-FU,811.0,3.7,3,12,154.0,130.08,-89.0,2,3,58.2,470.54,-42.65,5,15,106.1,4,0,Route: Specialized IV/Salts,Target: Rapid absorption. MBA: Focus on Acute Care/Hospital setting.
48,Vinblastine,Doxorubicin hydrochloride,811.0,3.7,3,12,154.0,543.5,1.27,6,12,206.0,677.25,2.485,9,24,180.0,2,3,Route: SC / IM Injection,Target: Long-acting release. MBA: Lifecycle management to extend patent life.
49,Vinblastine,Goserelin,811.0,3.7,3,12,154.0,1269.4,-2.0,17,16,496.0,1040.2,0.8500000000000001,20,28,325.0,1,4,Route: Complex Chemotherapy IV,Target: Specialized Oncology Centers. MBA: High barrier to entry for generics.
50,Vinblastine,Paclitaxel,811.0,3.7,3,12,154.0,853.9,3.0,4,14,221.0,832.45,3.35,7,26,187.5,2,3,Route: SC / IM Injection,Target: Long-acting release. MBA: Lifecycle management to extend patent life.
51,Vinblastine,Anastrozole,811.0,3.7,3,12,154.0,293.4,1.58,0,4,78.3,552.2,2.64,3,16,116.15,0,2,Route: Standard IV Infusion,Target: Clinical setting. MBA: Stable revenue through doctor 'Buy-and-Bill' model.
52,Vinblastine,Gemcitabine,811.0,3.7,3,12,154.0,1269.4,-2.0,17,16,496.0,1040.2,0.8500000000000001,20,28,325.0,1,4,Route: Complex Chemotherapy IV,Target: Specialized Oncology Centers. MBA: High barrier to entry for generics.
53,Vinblastine,Docetaxel,811.0,3.7,3,12,154.0,807.9,2.4,5,14,224.0,809.45,3.05,8,26,189.0,2,3,Route: SC / IM Injection,Target: Long-acting release. MBA: Lifecycle management to extend patent life.
54,Vinblastine,Letrozole,811.0,3.7,3,12,154.0,285.3,2.5,0,4,78.3,548.15,3.1,3,16,116.15,0,2,Route: Standard IV Infusion,Target: Clinical setting. MBA: Stable revenue through doctor 'Buy-and-Bill' model.
55,Vinblastine,Capecitabine,811.0,3.7,3,12,154.0,359.35,0.4,7,7,121.0,585.175,2.05,10,19,137.5,2,3,Route: SC / IM Injection,Target: Long-acting release. MBA: Lifecycle management to extend patent life.
56,Vinblastine,Exemestane,811.0,3.7,3,12,154.0,296.4,3.7,0,2,34.1,553.7,3.7,3,14,94.05,0,2,Route: Standard IV Infusion,Target: Clinical setting. MBA: Stable revenue through doctor 'Buy-and-Bill' model.
57,Vinblastine,Fulvestrant,811.0,3.7,3,12,154.0,606.8,8.9,2,9,76.7,708.9,6.300000000000001,5,21,115.35,2,3,Route: SC / IM Injection,Target: Long-acting release. MBA: Lifecycle management to extend patent life.
58,Vinblastine,Lapatinib,811.0,3.7,3,12,154.0,581.1,5.4,2,9,115.0,696.05,4.550000000000001,5,21,134.5,2,3,Route: SC / IM Injection,Target: Long-acting release. MBA: Lifecycle management to extend patent life.
59,Vinblastine,Palbociclib,811.0,3.7,3,12,154.0,447.5,0.99,2,8,103.0,629.25,2.345,5,20,128.5,2,3,Route: SC / IM Injection,Target: Long-acting release. MBA: Lifecycle management to extend patent life.
60,Vinblastine,Tucatinib,811.0,3.7,3,12,154.0,480.5,3.62,2,8,111.0,645.75,3.66,5,20,132.5,2,3,Route: SC / IM Injection,Target: Long-acting release. MBA: Lifecycle management to extend patent life.
61,Vinblastine,Epirubicin,811.0,3.7,3,12,154.0,543.5,-0.5,6,12,206.0,677.25,1.6,9,24,180.0,2,3,Route: SC / IM Injection,Target: Long-acting release. MBA: Lifecycle management to extend patent life.
62,Vinblastine,Megestrol acetate,811.0,3.7,3,12,154.0,384.5,3.2,0,4,60.4,597.75,3.45,3,16,107.2,0,2,Route: Standard IV Infusion,Target: Clinical setting. MBA: Stable revenue through doctor 'Buy-and-Bill' model.
63,Vinblastine,Toremifene,811.0,3.7,3,12,154.0,406.0,6.8,0,2,12.5,608.5,5.25,3,14,83.25,0,2,Route: Standard IV Infusion,Target: Clinical setting. MBA: Stable revenue through doctor 'Buy-and-Bill' model.
64,Vinblastine,Fluoxymesterone,811.0,3.7,3,12,154.0,336.4,2.38,2,4,57.5,573.7,3.04,5,16,105.75,0,2,Route: Standard IV Infusion,Target: Clinical setting. MBA: Stable revenue through doctor 'Buy-and-Bill' model.
65,Vinblastine,Thiotepa,811.0,3.7,3,12,154.0,189.22,0.53,4,3,41.1,500.11,2.115,7,15,97.55,0,2,Route: Standard IV Infusion,Target: Clinical setting. MBA: Stable revenue through doctor 'Buy-and-Bill' model.
66,Vinblastine,methyltestosterone,811.0,3.7,3,12,154.0,302.5,3.36,1,2,37.3,556.75,3.53,4,14,95.65,0,2,Route: Standard IV Infusion,Target: Clinical setting. MBA: Stable revenue through doctor 'Buy-and-Bill' model.
67,Vinblastine,Pamidronate,811.0,3.7,3,12,154.0,235.07,-4.7,6,8,161.0,523.035,-0.5,9,20,157.5,2,3,Route: SC / IM Injection,Target: Long-acting release. MBA: Lifecycle management to extend patent life.
68,5-FU,Doxorubicin hydrochloride,130.08,-89.0,2,3,58.2,543.5,1.27,6,12,206.0,336.79,-43.865,8,15,132.1,4,0,Route: Specialized IV/Salts,Target: Rapid absorption. MBA: Focus on Acute Care/Hospital setting.
70,5-FU,Goserelin,130.08,-89.0,2,3,58.2,1269.4,-2.0,17,16,496.0,699.74,-45.5,19,19,277.1,1,4,Route: Complex Chemotherapy IV,Target: Specialized Oncology Centers. MBA: High barrier to entry for generics.
71,5-FU,Paclitaxel,130.08,-89.0,2,3,58.2,853.9,3.0,4,14,221.0,491.99,-43.0,6,17,139.6,4,0,Route: Specialized IV/Salts,Target: Rapid absorption. MBA: Focus on Acute Care/Hospital setting.
72,5-FU,Anastrozole,130.08,-89.0,2,3,58.2,293.4,1.58,0,4,78.3,211.74,-43.71,2,7,68.25,4,0,Route: Specialized IV/Salts,Target: Rapid absorption. MBA: Focus on Acute Care/Hospital setting.
73,5-FU,Gemcitabine,130.08,-89.0,2,3,58.2,1269.4,-2.0,17,16,496.0,699.74,-45.5,19,19,277.1,1,4,Route: Complex Chemotherapy IV,Target: Specialized Oncology Centers. MBA: High barrier to entry for generics.
74,5-FU,Docetaxel,130.08,-89.0,2,3,58.2,807.9,2.4,5,14,224.0,468.99,-43.3,7,17,141.1,4,0,Route: Specialized IV/Salts,Target: Rapid absorption. MBA: Focus on Acute Care/Hospital setting.
75,5-FU,Letrozole,130.08,-89.0,2,3,58.2,285.3,2.5,0,4,78.3,207.69,-43.25,2,7,68.25,4,0,Route: Specialized IV/Salts,Target: Rapid absorption. MBA: Focus on Acute Care/Hospital setting.
76,5-FU,Capecitabine,130.08,-89.0,2,3,58.2,359.35,0.4,7,7,121.0,244.715,-44.3,9,10,89.6,4,0,Route: Specialized IV/Salts,Target: Rapid absorption. MBA: Focus on Acute Care/Hospital setting.
77,5-FU,Exemestane,130.08,-89.0,2,3,58.2,296.4,3.7,0,2,34.1,213.24,-42.65,2,5,46.15000000000001,4,0,Route: Specialized IV/Salts,Target: Rapid absorption. MBA: Focus on Acute Care/Hospital setting.
78,5-FU,Fulvestrant,130.08,-89.0,2,3,58.2,606.8,8.9,2,9,76.7,368.44,-40.05,4,12,67.45,4,0,Route: Specialized IV/Salts,Target: Rapid absorption. MBA: Focus on Acute Care/Hospital setting.
79,5-FU,Lapatinib,130.08,-89.0,2,3,58.2,581.1,5.4,2,9,115.0,355.59,-41.8,4,12,86.6,4,0,Route: Specialized IV/Salts,Target: Rapid absorption. MBA: Focus on Acute Care/Hospital setting.
80,5-FU,Palbociclib,130.08,-89.0,2,3,58.2,447.5,0.99,2,8,103.0,288.79,-44.005,4,11,80.6,4,0,Route: Specialized IV/Salts,Target: Rapid absorption. MBA: Focus on Acute Care/Hospital setting.
81,5-FU,Tucatinib,130.08,-89.0,2,3,58.2,480.5,3.62,2,8,111.0,305.29,-42.69,4,11,84.6,4,0,Route: Specialized IV/Salts,Target: Rapid absorption. MBA: Focus on Acute Care/Hospital setting.
82,5-FU,Epirubicin,130.08,-89.0,2,3,58.2,543.5,-0.5,6,12,206.0,336.79,-44.75,8,15,132.1,4,0,Route: Specialized IV/Salts,Target: Rapid absorption. MBA: Focus on Acute Care/Hospital setting.
83,5-FU,Megestrol acetate,130.08,-89.0,2,3,58.2,384.5,3.2,0,4,60.4,257.29,-42.9,2,7,59.3,4,0,Route: Specialized IV/Salts,Target: Rapid absorption. MBA: Focus on Acute Care/Hospital setting.
84,5-FU,Toremifene,130.08,-89.0,2,3,58.2,406.0,6.8,0,2,12.5,268.04,-41.1,2,5,35.35,4,0,Route: Specialized IV/Salts,Target: Rapid absorption. MBA: Focus on Acute Care/Hospital setting.
85,5-FU,Fluoxymesterone,130.08,-89.0,2,3,58.2,336.4,2.38,2,4,57.5,233.24,-43.31,4,7,57.85,4,0,Route: Specialized IV/Salts,Target: Rapid absorption. MBA: Focus on Acute Care/Hospital setting.
86,5-FU,Thiotepa,130.08,-89.0,2,3,58.2,189.22,0.53,4,3,41.1,159.65,-44.235,6,6,49.65000000000001,4,0,Route: Specialized IV/Salts,Target: Rapid absorption. MBA: Focus on Acute Care/Hospital setting.
87,5-FU,methyltestosterone,130.08,-89.0,2,3,58.2,302.5,3.36,1,2,37.3,216.29,-42.82,3,5,47.75,4,0,Route: Specialized IV/Salts,Target: Rapid absorption. MBA: Focus on Acute Care/Hospital setting.
88,5-FU,Pamidronate,130.08,-89.0,2,3,58.2,235.07,-4.7,6,8,161.0,182.575,-46.85,8,11,109.6,4,0,Route: Specialized IV/Salts,Target: Rapid absorption. MBA: Focus on Acute Care/Hospital setting.
89,Doxorubicin hydrochloride,Goserelin,543.5,1.27,6,12,206.0,1269.4,-2.0,17,16,496.0,906.45,-0.365,23,28,351.0,1,4,Route: Complex Chemotherapy IV,Target: Specialized Oncology Centers. MBA: High barrier to entry for generics.
90,Doxorubicin hydrochloride,Paclitaxel,543.5,1.27,6,12,206.0,853.9,3.0,4,14,221.0,698.7,2.135,10,26,213.5,2,3,Route: SC / IM Injection,Target: Long-acting release. MBA: Lifecycle management to extend patent life.
91,Doxorubicin hydrochloride,Anastrozole,543.5,1.27,6,12,206.0,293.4,1.58,0,4,78.3,418.45,1.425,6,16,142.15,0,2,Route: Standard IV Infusion,Target: Clinical setting. MBA: Stable revenue through doctor 'Buy-and-Bill' model.
92,Doxorubicin hydrochloride,Gemcitabine,543.5,1.27,6,12,206.0,1269.4,-2.0,17,16,496.0,906.45,-0.365,23,28,351.0,1,4,Route: Complex Chemotherapy IV,Target: Specialized Oncology Centers. MBA: High barrier to entry for generics.
93,Doxorubicin hydrochloride,Docetaxel,543.5,1.27,6,12,206.0,807.9,2.4,5,14,224.0,675.7,1.835,11,26,215.0,2,3,Route: SC / IM Injection,Target: Long-acting release. MBA: Lifecycle management to extend patent life.
94,Doxorubicin hydrochloride,Letrozole,543.5,1.27,6,12,206.0,285.3,2.5,0,4,78.3,414.4,1.885,6,16,142.15,0,2,Route: Standard IV Infusion,Target: Clinical setting. MBA: Stable revenue through doctor 'Buy-and-Bill' model.
95,Doxorubicin hydrochloride,Capecitabine,543.5,1.27,6,12,206.0,359.35,0.4,7,7,121.0,451.425,0.835,13,19,163.5,2,3,Route: SC / IM Injection,Target: Long-acting release. MBA: Lifecycle management to extend patent life.
96,Doxorubicin hydrochloride,Exemestane,543.5,1.27,6,12,206.0,296.4,3.7,0,2,34.1,419.95,2.485,6,14,120.05,0,2,Route: Standard IV Infusion,Target: Clinical setting. MBA: Stable revenue through doctor 'Buy-and-Bill' model.
97,Doxorubicin hydrochloride,Fulvestrant,543.5,1.27,6,12,206.0,606.8,8.9,2,9,76.7,575.15,5.085,8,21,141.35,2,3,Route: SC / IM Injection,Target: Long-acting release. MBA: Lifecycle management to extend patent life.
98,Doxorubicin hydrochloride,Lapatinib,543.5,1.27,6,12,206.0,581.1,5.4,2,9,115.0,562.3,3.335,8,21,160.5,2,3,Route: SC / IM Injection,Target: Long-acting release. MBA: Lifecycle management to extend patent life.
99,Doxorubicin hydrochloride,Palbociclib,543.5,1.27,6,12,206.0,447.5,0.99,2,8,103.0,495.5,1.13,8,20,154.5,2,3,Route: SC / IM Injection,Target: Long-acting release. MBA: Lifecycle management to extend patent life.
100,Doxorubicin hydrochloride,Tucatinib,543.5,1.27,6,12,206.0,480.5,3.62,2,8,111.0,512.0,2.445,8,20,158.5,2,3,Route: SC / IM Injection,Target: Long-acting release. MBA: Lifecycle management to extend patent life.
101,Doxorubicin hydrochloride,Epirubicin,543.5,1.27,6,12,206.0,543.5,-0.5,6,12,206.0,543.5,0.385,12,24,206.0,2,3,Route: SC / IM Injection,Target: Long-acting release. MBA: Lifecycle management to extend patent life.
102,Doxorubicin hydrochloride,Megestrol acetate,543.5,1.27,6,12,206.0,384.5,3.2,0,4,60.4,464.0,2.235,6,16,133.2,0,2,Route: Standard IV Infusion,Target: Clinical setting. MBA: Stable revenue through doctor 'Buy-and-Bill' model.
103,Doxorubicin hydrochloride,Toremifene,543.5,1.27,6,12,206.0,406.0,6.8,0,2,12.5,474.75,4.035,6,14,109.25,0,2,Route: Standard IV Infusion,Target: Clinical setting. MBA: Stable revenue through doctor 'Buy-and-Bill' model.
104,Doxorubicin hydrochloride,Fluoxymesterone,543.5,1.27,6,12,206.0,336.4,2.38,2,4,57.5,439.95,1.825,8,16,131.75,0,2,Route: Standard IV Infusion,Target: Clinical setting. MBA: Stable revenue through doctor 'Buy-and-Bill' model.
105,Doxorubicin hydrochloride,Thiotepa,543.5,1.27,6,12,206.0,189.22,0.53,4,3,41.1,366.36,0.9,10,15,123.55,0,2,Route: Standard IV Infusion,Target: Clinical setting. MBA: Stable revenue through doctor 'Buy-and-Bill' model.
106,Doxorubicin hydrochloride,methyltestosterone,543.5,1.27,6,12,206.0,302.5,3.36,1,2,37.3,423.0,2.315,7,14,121.65,0,2,Route: Standard IV Infusion,Target: Clinical setting. MBA: Stable revenue through doctor 'Buy-and-Bill' model.
107,Doxorubicin hydrochloride,Pamidronate,543.5,1.27,6,12,206.0,235.07,-4.7,6,8,161.0,389.285,-1.715,12,20,183.5,2,3,Route: SC / IM Injection,Target: Long-acting release. MBA: Lifecycle management to extend patent life.
108,Goserelin,Paclitaxel,1269.4,-2.0,17,16,496.0,853.9,3.0,4,14,221.0,1061.65,0.5,21,30,358.5,1,4,Route: Complex Chemotherapy IV,Target: Specialized Oncology Centers. MBA: High barrier to entry for generics.
109,Goserelin,Anastrozole,1269.4,-2.0,17,16,496.0,293.4,1.58,0,4,78.3,781.4000000000001,-0.21,17,20,287.15,1,4,Route: Complex Chemotherapy IV,Target: Specialized Oncology Centers. MBA: High barrier to entry for generics.
110,Goserelin,Gemcitabine,1269.4,-2.0,17,16,496.0,1269.4,-2.0,17,16,496.0,1269.4,-2.0,34,32,496.0,1,4,Route: Complex Chemotherapy IV,Target: Specialized Oncology Centers. MBA: High barrier to entry for generics.
111,Goserelin,Docetaxel,1269.4,-2.0,17,16,496.0,807.9,2.4,5,14,224.0,1038.65,0.2,22,30,360.0,1,4,Route: Complex Chemotherapy IV,Target: Specialized Oncology Centers. MBA: High barrier to entry for generics.
112,Goserelin,Letrozole,1269.4,-2.0,17,16,496.0,285.3,2.5,0,4,78.3,777.35,0.25,17,20,287.15,1,4,Route: Complex Chemotherapy IV,Target: Specialized Oncology Centers. MBA: High barrier to entry for generics.
113,Goserelin,Capecitabine,1269.4,-2.0,17,16,496.0,359.35,0.4,7,7,121.0,814.375,-0.8,24,23,308.5,1,4,Route: Complex Chemotherapy IV,Target: Specialized Oncology Centers. MBA: High barrier to entry for generics.
114,Goserelin,Exemestane,1269.4,-2.0,17,16,496.0,296.4,3.7,0,2,34.1,782.9000000000001,0.8500000000000001,17,18,265.05,1,4,Route: Complex Chemotherapy IV,Target: Specialized Oncology Centers. MBA: High barrier to entry for generics.
115,Goserelin,Fulvestrant,1269.4,-2.0,17,16,496.0,606.8,8.9,2,9,76.7,938.1,3.45,19,25,286.35,1,4,Route: Complex Chemotherapy IV,Target: Specialized Oncology Centers. MBA: High barrier to entry for generics.
116,Goserelin,Lapatinib,1269.4,-2.0,17,16,496.0,581.1,5.4,2,9,115.0,925.25,1.7,19,25,305.5,1,4,Route: Complex Chemotherapy IV,Target: Specialized Oncology Centers. MBA: High barrier to entry for generics.
117,Goserelin,Palbociclib,1269.4,-2.0,17,16,496.0,447.5,0.99,2,8,103.0,858.45,-0.505,19,24,299.5,1,4,Route: Complex Chemotherapy IV,Target: Specialized Oncology Centers. MBA: High barrier to entry for generics.
118,Goserelin,Tucatinib,1269.4,-2.0,17,16,496.0,480.5,3.62,2,8,111.0,874.95,0.81,19,24,303.5,1,4,Route: Complex Chemotherapy IV,Target: Specialized Oncology Centers. MBA: High barrier to entry for generics.
119,Goserelin,Epirubicin,1269.4,-2.0,17,16,496.0,543.5,-0.5,6,12,206.0,906.45,-1.25,23,28,351.0,1,4,Route: Complex Chemotherapy IV,Target: Specialized Oncology Centers. MBA: High barrier to entry for generics.
120,Goserelin,Megestrol acetate,1269.4,-2.0,17,16,496.0,384.5,3.2,0,4,60.4,826.95,0.6000000000000001,17,20,278.2,1,4,Route: Complex Chemotherapy IV,Target: Specialized Oncology Centers. MBA: High barrier to entry for generics.
121,Goserelin,Toremifene,1269.4,-2.0,17,16,496.0,406.0,6.8,0,2,12.5,837.7,2.4,17,18,254.25,1,4,Route: Complex Chemotherapy IV,Target: Specialized Oncology Centers. MBA: High barrier to entry for generics.
122,Goserelin,Fluoxymesterone,1269.4,-2.0,17,16,496.0,336.4,2.38,2,4,57.5,802.9000000000001,0.1899999999999999,19,20,276.75,1,4,Route: Complex Chemotherapy IV,Target: Specialized Oncology Centers. MBA: High barrier to entry for generics.
123,Goserelin,Thiotepa,1269.4,-2.0,17,16,496.0,189.22,0.53,4,3,41.1,729.3100000000001,-0.735,21,19,268.55,1,4,Route: Complex Chemotherapy IV,Target: Specialized Oncology Centers. MBA: High barrier to entry for generics.
124,Goserelin,methyltestosterone,1269.4,-2.0,17,16,496.0,302.5,3.36,1,2,37.3,785.95,0.6799999999999999,18,18,266.65,1,4,Route: Complex Chemotherapy IV,Target: Specialized Oncology Centers. MBA: High barrier to entry for generics.
125,Goserelin,Pamidronate,1269.4,-2.0,17,16,496.0,235.07,-4.7,6,8,161.0,752.235,-3.35,23,24,328.5,1,4,Route: Complex Chemotherapy IV,Target: Specialized Oncology Centers. MBA: High barrier to entry for generics.
126,Paclitaxel,Anastrozole,853.9,3.0,4,14,221.0,293.4,1.58,0,4,78.3,573.65,2.29,4,18,149.65,2,3,Route: SC / IM Injection,Target: Long-acting release. MBA: Lifecycle management to extend patent life.
127,Paclitaxel,Gemcitabine,853.9,3.0,4,14,221.0,1269.4,-2.0,17,16,496.0,1061.65,0.5,21,30,358.5,1,4,Route: Complex Chemotherapy IV,Target: Specialized Oncology Centers. MBA: High barrier to entry for generics.
128,Paclitaxel,Docetaxel,853.9,3.0,4,14,221.0,807.9,2.4,5,14,224.0,830.9,2.7,9,28,222.5,2,3,Route: SC / IM Injection,Target: Long-acting release. MBA: Lifecycle management to extend patent life.
129,Paclitaxel,Letrozole,853.9,3.0,4,14,221.0,285.3,2.5,0,4,78.3,569.6,2.75,4,18,149.65,2,3,Route: SC / IM Injection,Target: Long-acting release. MBA: Lifecycle management to extend patent life.
130,Paclitaxel,Capecitabine,853.9,3.0,4,14,221.0,359.35,0.4,7,7,121.0,606.625,1.7,11,21,171.0,2,3,Route: SC / IM Injection,Target: Long-acting release. MBA: Lifecycle management to extend patent life.
131,Paclitaxel,Exemestane,853.9,3.0,4,14,221.0,296.4,3.7,0,2,34.1,575.15,3.35,4,16,127.55,0,2,Route: Standard IV Infusion,Target: Clinical setting. MBA: Stable revenue through doctor 'Buy-and-Bill' model.
132,Paclitaxel,Fulvestrant,853.9,3.0,4,14,221.0,606.8,8.9,2,9,76.7,730.3499999999999,5.95,6,23,148.85,2,3,Route: SC / IM Injection,Target: Long-acting release. MBA: Lifecycle management to extend patent life.
133,Paclitaxel,Lapatinib,853.9,3.0,4,14,221.0,581.1,5.4,2,9,115.0,717.5,4.2,6,23,168.0,2,3,Route: SC / IM Injection,Target: Long-acting release. MBA: Lifecycle management to extend patent life.
134,Paclitaxel,Palbociclib,853.9,3.0,4,14,221.0,447.5,0.99,2,8,103.0,650.7,1.995,6,22,162.0,2,3,Route: SC / IM Injection,Target: Long-acting release. MBA: Lifecycle management to extend patent life.
135,Paclitaxel,Tucatinib,853.9,3.0,4,14,221.0,480.5,3.62,2,8,111.0,667.2,3.31,6,22,166.0,2,3,Route: SC / IM Injection,Target: Long-acting release. MBA: Lifecycle management to extend patent life.
136,Paclitaxel,Epirubicin,853.9,3.0,4,14,221.0,543.5,-0.5,6,12,206.0,698.7,1.25,10,26,213.5,2,3,Route: SC / IM Injection,Target: Long-acting release. MBA: Lifecycle management to extend patent life.
137,Paclitaxel,Megestrol acetate,853.9,3.0,4,14,221.0,384.5,3.2,0,4,60.4,619.2,3.1,4,18,140.7,2,3,Route: SC / IM Injection,Target: Long-acting release. MBA: Lifecycle management to extend patent life.
138,Paclitaxel,Toremifene,853.9,3.0,4,14,221.0,406.0,6.8,0,2,12.5,629.95,4.9,4,16,116.75,0,2,Route: Standard IV Infusion,Target: Clinical setting. MBA: Stable revenue through doctor 'Buy-and-Bill' model.
139,Paclitaxel,Fluoxymesterone,853.9,3.0,4,14,221.0,336.4,2.38,2,4,57.5,595.15,2.69,6,18,139.25,2,3,Route: SC / IM Injection,Target: Long-acting release. MBA: Lifecycle management to extend patent life.
140,Paclitaxel,Thiotepa,853.9,3.0,4,14,221.0,189.22,0.53,4,3,41.1,521.56,1.765,8,17,131.05,0,2,Route: Standard IV Infusion,Target: Clinical setting. MBA: Stable revenue through doctor 'Buy-and-Bill' model.
141,Paclitaxel,methyltestosterone,853.9,3.0,4,14,221.0,302.5,3.36,1,2,37.3,578.2,3.18,5,16,129.15,0,2,Route: Standard IV Infusion,Target: Clinical setting. MBA: Stable revenue through doctor 'Buy-and-Bill' model.
142,Paclitaxel,Pamidronate,853.9,3.0,4,14,221.0,235.07,-4.7,6,8,161.0,544.485,-0.8500000000000001,10,22,191.0,2,3,Route: SC / IM Injection,Target: Long-acting release. MBA: Lifecycle management to extend patent life.
143,Anastrozole,Gemcitabine,293.4,1.58,0,4,78.3,1269.4,-2.0,17,16,496.0,781.4000000000001,-0.21,17,20,287.15,1,4,Route: Complex Chemotherapy IV,Target: Specialized Oncology Centers. MBA: High barrier to entry for generics.
144,Anastrozole,Docetaxel,293.4,1.58,0,4,78.3,807.9,2.4,5,14,224.0,550.65,1.99,5,18,151.15,0,2,Route: Standard IV Infusion,Target: Clinical setting. MBA: Stable revenue through doctor 'Buy-and-Bill' model.
145,Anastrozole,Letrozole,293.4,1.58,0,4,78.3,285.3,2.5,0,4,78.3,289.35,2.04,0,8,78.3,3,1,Route: Oral (Pill/Capsule),Target: Home-based care. MBA: High valuation for patient convenience (FDC potential).
146,Anastrozole,Capecitabine,293.4,1.58,0,4,78.3,359.35,0.4,7,7,121.0,326.375,0.99,7,11,99.65,3,1,Route: Oral (Pill/Capsule),Target: Home-based care. MBA: High valuation for patient convenience (FDC potential).
147,Anastrozole,Exemestane,293.4,1.58,0,4,78.3,296.4,3.7,0,2,34.1,294.9,2.64,0,6,56.2,3,1,Route: Oral (Pill/Capsule),Target: Home-based care. MBA: High valuation for patient convenience (FDC potential).
148,Anastrozole,Fulvestrant,293.4,1.58,0,4,78.3,606.8,8.9,2,9,76.7,450.1,5.24,2,13,77.5,3,1,Route: Oral (Pill/Capsule),Target: Home-based care. MBA: High valuation for patient convenience (FDC potential).
149,Anastrozole,Lapatinib,293.4,1.58,0,4,78.3,581.1,5.4,2,9,115.0,437.25,3.49,2,13,96.65,3,1,Route: Oral (Pill/Capsule),Target: Home-based care. MBA: High valuation for patient convenience (FDC potential).
150,Anastrozole,Palbociclib,293.4,1.58,0,4,78.3,447.5,0.99,2,8,103.0,370.45,1.285,2,12,90.65,3,1,Route: Oral (Pill/Capsule),Target: Home-based care. MBA: High valuation for patient convenience (FDC potential).
151,Anastrozole,Tucatinib,293.4,1.58,0,4,78.3,480.5,3.62,2,8,111.0,386.95,2.6,2,12,94.65,3,1,Route: Oral (Pill/Capsule),Target: Home-based care. MBA: High valuation for patient convenience (FDC potential).
152,Anastrozole,Epirubicin,293.4,1.58,0,4,78.3,543.5,-0.5,6,12,206.0,418.45,0.54,6,16,142.15,0,2,Route: Standard IV Infusion,Target: Clinical setting. MBA: Stable revenue through doctor 'Buy-and-Bill' model.
153,Anastrozole,Megestrol acetate,293.4,1.58,0,4,78.3,384.5,3.2,0,4,60.4,338.95,2.39,0,8,69.35,3,1,Route: Oral (Pill/Capsule),Target: Home-based care. MBA: High valuation for patient convenience (FDC potential).
154,Anastrozole,Toremifene,293.4,1.58,0,4,78.3,406.0,6.8,0,2,12.5,349.7,4.19,0,6,45.4,3,1,Route: Oral (Pill/Capsule),Target: Home-based care. MBA: High valuation for patient convenience (FDC potential).
155,Anastrozole,Fluoxymesterone,293.4,1.58,0,4,78.3,336.4,2.38,2,4,57.5,314.9,1.98,2,8,67.9,3,1,Route: Oral (Pill/Capsule),Target: Home-based care. MBA: High valuation for patient convenience (FDC potential).
156,Anastrozole,Thiotepa,293.4,1.58,0,4,78.3,189.22,0.53,4,3,41.1,241.31,1.055,4,7,59.7,3,1,Route: Oral (Pill/Capsule),Target: Home-based care. MBA: High valuation for patient convenience (FDC potential).
157,Anastrozole,methyltestosterone,293.4,1.58,0,4,78.3,302.5,3.36,1,2,37.3,297.95,2.47,1,6,57.8,3,1,Route: Oral (Pill/Capsule),Target: Home-based care. MBA: High valuation for patient convenience (FDC potential).
158,Anastrozole,Pamidronate,293.4,1.58,0,4,78.3,235.07,-4.7,6,8,161.0,264.235,-1.56,6,12,119.65,0,2,Route: Standard IV Infusion,Target: Clinical setting. MBA: Stable revenue through doctor 'Buy-and-Bill' model.
159,Gemcitabine,Docetaxel,1269.4,-2.0,17,16,496.0,807.9,2.4,5,14,224.0,1038.65,0.2,22,30,360.0,1,4,Route: Complex Chemotherapy IV,Target: Specialized Oncology Centers. MBA: High barrier to entry for generics.
160,Gemcitabine,Letrozole,1269.4,-2.0,17,16,496.0,285.3,2.5,0,4,78.3,777.35,0.25,17,20,287.15,1,4,Route: Complex Chemotherapy IV,Target: Specialized Oncology Centers. MBA: High barrier to entry for generics.
161,Gemcitabine,Capecitabine,1269.4,-2.0,17,16,496.0,359.35,0.4,7,7,121.0,814.375,-0.8,24,23,308.5,1,4,Route: Complex Chemotherapy IV,Target: Specialized Oncology Centers. MBA: High barrier to entry for generics.
162,Gemcitabine,Exemestane,1269.4,-2.0,17,16,496.0,296.4,3.7,0,2,34.1,782.9000000000001,0.8500000000000001,17,18,265.05,1,4,Route: Complex Chemotherapy IV,Target: Specialized Oncology Centers. MBA: High barrier to entry for generics.
163,Gemcitabine,Fulvestrant,1269.4,-2.0,17,16,496.0,606.8,8.9,2,9,76.7,938.1,3.45,19,25,286.35,1,4,Route: Complex Chemotherapy IV,Target: Specialized Oncology Centers. MBA: High barrier to entry for generics.
164,Gemcitabine,Lapatinib,1269.4,-2.0,17,16,496.0,581.1,5.4,2,9,115.0,925.25,1.7,19,25,305.5,1,4,Route: Complex Chemotherapy IV,Target: Specialized Oncology Centers. MBA: High barrier to entry for generics.
165,Gemcitabine,Palbociclib,1269.4,-2.0,17,16,496.0,447.5,0.99,2,8,103.0,858.45,-0.505,19,24,299.5,1,4,Route: Complex Chemotherapy IV,Target: Specialized Oncology Centers. MBA: High barrier to entry for generics.
166,Gemcitabine,Tucatinib,1269.4,-2.0,17,16,496.0,480.5,3.62,2,8,111.0,874.95,0.81,19,24,303.5,1,4,Route: Complex Chemotherapy IV,Target: Specialized Oncology Centers. MBA: High barrier to entry for generics.
167,Gemcitabine,Epirubicin,1269.4,-2.0,17,16,496.0,543.5,-0.5,6,12,206.0,906.45,-1.25,23,28,351.0,1,4,Route: Complex Chemotherapy IV,Target: Specialized Oncology Centers. MBA: High barrier to entry for generics.
168,Gemcitabine,Megestrol acetate,1269.4,-2.0,17,16,496.0,384.5,3.2,0,4,60.4,826.95,0.6000000000000001,17,20,278.2,1,4,Route: Complex Chemotherapy IV,Target: Specialized Oncology Centers. MBA: High barrier to entry for generics.
169,Gemcitabine,Toremifene,1269.4,-2.0,17,16,496.0,406.0,6.8,0,2,12.5,837.7,2.4,17,18,254.25,1,4,Route: Complex Chemotherapy IV,Target: Specialized Oncology Centers. MBA: High barrier to entry for generics.
170,Gemcitabine,Fluoxymesterone,1269.4,-2.0,17,16,496.0,336.4,2.38,2,4,57.5,802.9000000000001,0.1899999999999999,19,20,276.75,1,4,Route: Complex Chemotherapy IV,Target: Specialized Oncology Centers. MBA: High barrier to entry for generics.
171,Gemcitabine,Thiotepa,1269.4,-2.0,17,16,496.0,189.22,0.53,4,3,41.1,729.3100000000001,-0.735,21,19,268.55,1,4,Route: Complex Chemotherapy IV,Target: Specialized Oncology Centers. MBA: High barrier to entry for generics.
172,Gemcitabine,methyltestosterone,1269.4,-2.0,17,16,496.0,302.5,3.36,1,2,37.3,785.95,0.6799999999999999,18,18,266.65,1,4,Route: Complex Chemotherapy IV,Target: Specialized Oncology Centers. MBA: High barrier to entry for generics.
173,Gemcitabine,Pamidronate,1269.4,-2.0,17,16,496.0,235.07,-4.7,6,8,161.0,752.235,-3.35,23,24,328.5,1,4,Route: Complex Chemotherapy IV,Target: Specialized Oncology Centers. MBA: High barrier to entry for generics.
174,Docetaxel,Letrozole,807.9,2.4,5,14,224.0,285.3,2.5,0,4,78.3,546.6,2.45,5,18,151.15,0,2,Route: Standard IV Infusion,Target: Clinical setting. MBA: Stable revenue through doctor 'Buy-and-Bill' model.
175,Docetaxel,Capecitabine,807.9,2.4,5,14,224.0,359.35,0.4,7,7,121.0,583.625,1.4,12,21,172.5,2,3,Route: SC / IM Injection,Target: Long-acting release. MBA: Lifecycle management to extend patent life.
176,Docetaxel,Exemestane,807.9,2.4,5,14,224.0,296.4,3.7,0,2,34.1,552.15,3.05,5,16,129.05,0,2,Route: Standard IV Infusion,Target: Clinical setting. MBA: Stable revenue through doctor 'Buy-and-Bill' model.
177,Docetaxel,Fulvestrant,807.9,2.4,5,14,224.0,606.8,8.9,2,9,76.7,707.3499999999999,5.65,7,23,150.35,2,3,Route: SC / IM Injection,Target: Long-acting release. MBA: Lifecycle management to extend patent life.
178,Docetaxel,Lapatinib,807.9,2.4,5,14,224.0,581.1,5.4,2,9,115.0,694.5,3.9,7,23,169.5,2,3,Route: SC / IM Injection,Target: Long-acting release. MBA: Lifecycle management to extend patent life.
179,Docetaxel,Palbociclib,807.9,2.4,5,14,224.0,447.5,0.99,2,8,103.0,627.7,1.695,7,22,163.5,2,3,Route: SC / IM Injection,Target: Long-acting release. MBA: Lifecycle management to extend patent life.
180,Docetaxel,Tucatinib,807.9,2.4,5,14,224.0,480.5,3.62,2,8,111.0,644.2,3.01,7,22,167.5,2,3,Route: SC / IM Injection,Target: Long-acting release. MBA: Lifecycle management to extend patent life.
181,Docetaxel,Epirubicin,807.9,2.4,5,14,224.0,543.5,-0.5,6,12,206.0,675.7,0.95,11,26,215.0,2,3,Route: SC / IM Injection,Target: Long-acting release. MBA: Lifecycle management to extend patent life.
182,Docetaxel,Megestrol acetate,807.9,2.4,5,14,224.0,384.5,3.2,0,4,60.4,596.2,2.8,5,18,142.2,2,3,Route: SC / IM Injection,Target: Long-acting release. MBA: Lifecycle management to extend patent life.
183,Docetaxel,Toremifene,807.9,2.4,5,14,224.0,406.0,6.8,0,2,12.5,606.95,4.6,5,16,118.25,0,2,Route: Standard IV Infusion,Target: Clinical setting. MBA: Stable revenue through doctor 'Buy-and-Bill' model.
184,Docetaxel,Fluoxymesterone,807.9,2.4,5,14,224.0,336.4,2.38,2,4,57.5,572.15,2.39,7,18,140.75,2,3,Route: SC / IM Injection,Target: Long-acting release. MBA: Lifecycle management to extend patent life.
185,Docetaxel,Thiotepa,807.9,2.4,5,14,224.0,189.22,0.53,4,3,41.1,498.56,1.465,9,17,132.55,0,2,Route: Standard IV Infusion,Target: Clinical setting. MBA: Stable revenue through doctor 'Buy-and-Bill' model.
186,Docetaxel,methyltestosterone,807.9,2.4,5,14,224.0,302.5,3.36,1,2,37.3,555.2,2.88,6,16,130.65,0,2,Route: Standard IV Infusion,Target: Clinical setting. MBA: Stable revenue through doctor 'Buy-and-Bill' model.
187,Docetaxel,Pamidronate,807.9,2.4,5,14,224.0,235.07,-4.7,6,8,161.0,521.485,-1.15,11,22,192.5,2,3,Route: SC / IM Injection,Target: Long-acting release. MBA: Lifecycle management to extend patent life.
188,Letrozole,Capecitabine,285.3,2.5,0,4,78.3,359.35,0.4,7,7,121.0,322.325,1.45,7,11,99.65,3,1,Route: Oral (Pill/Capsule),Target: Home-based care. MBA: High valuation for patient convenience (FDC potential).
189,Letrozole,Exemestane,285.3,2.5,0,4,78.3,296.4,3.7,0,2,34.1,290.85,3.1,0,6,56.2,3,1,Route: Oral (Pill/Capsule),Target: Home-based care. MBA: High valuation for patient convenience (FDC potential).
190,Letrozole,Fulvestrant,285.3,2.5,0,4,78.3,606.8,8.9,2,9,76.7,446.05,5.7,2,13,77.5,3,1,Route: Oral (Pill/Capsule),Target: Home-based care. MBA: High valuation for patient convenience (FDC potential).
191,Letrozole,Lapatinib,285.3,2.5,0,4,78.3,581.1,5.4,2,9,115.0,433.2,3.95,2,13,96.65,3,1,Route: Oral (Pill/Capsule),Target: Home-based care. MBA: High valuation for patient convenience (FDC potential).
192,Letrozole,Palbociclib,285.3,2.5,0,4,78.3,447.5,0.99,2,8,103.0,366.4,1.745,2,12,90.65,3,1,Route: Oral (Pill/Capsule),Target: Home-based care. MBA: High valuation for patient convenience (FDC potential).
193,Letrozole,Tucatinib,285.3,2.5,0,4,78.3,480.5,3.62,2,8,111.0,382.9,3.06,2,12,94.65,3,1,Route: Oral (Pill/Capsule),Target: Home-based care. MBA: High valuation for patient convenience (FDC potential).
194,Letrozole,Epirubicin,285.3,2.5,0,4,78.3,543.5,-0.5,6,12,206.0,414.4,1.0,6,16,142.15,0,2,Route: Standard IV Infusion,Target: Clinical setting. MBA: Stable revenue through doctor 'Buy-and-Bill' model.
195,Letrozole,Megestrol acetate,285.3,2.5,0,4,78.3,384.5,3.2,0,4,60.4,334.9,2.85,0,8,69.35,3,1,Route: Oral (Pill/Capsule),Target: Home-based care. MBA: High valuation for patient convenience (FDC potential).
196,Letrozole,Toremifene,285.3,2.5,0,4,78.3,406.0,6.8,0,2,12.5,345.65,4.65,0,6,45.4,3,1,Route: Oral (Pill/Capsule),Target: Home-based care. MBA: High valuation for patient convenience (FDC potential).
198,Letrozole,Fluoxymesterone,285.3,2.5,0,4,78.3,336.4,2.38,2,4,57.5,310.85,2.44,2,8,67.9,3,1,Route: Oral (Pill/Capsule),Target: Home-based care. MBA: High valuation for patient convenience (FDC potential).
199,Letrozole,Thiotepa,285.3,2.5,0,4,78.3,189.22,0.53,4,3,41.1,237.26,1.515,4,7,59.7,3,1,Route: Oral (Pill/Capsule),Target: Home-based care. MBA: High valuation for patient convenience (FDC potential).
200,Letrozole,methyltestosterone,285.3,2.5,0,4,78.3,302.5,3.36,1,2,37.3,293.9,2.93,1,6,57.8,3,1,Route: Oral (Pill/Capsule),Target: Home-based care. MBA: High valuation for patient convenience (FDC potential).
201,Letrozole,Pamidronate,285.3,2.5,0,4,78.3,235.07,-4.7,6,8,161.0,260.185,-1.1,6,12,119.65,0,2,Route: Standard IV Infusion,Target: Clinical setting. MBA: Stable revenue through doctor 'Buy-and-Bill' model.
202,Capecitabine,Exemestane,359.35,0.4,7,7,121.0,296.4,3.7,0,2,34.1,327.875,2.05,7,9,77.55,3,1,Route: Oral (Pill/Capsule),Target: Home-based care. MBA: High valuation for patient convenience (FDC potential).
203,Capecitabine,Fulvestrant,359.35,0.4,7,7,121.0,606.8,8.9,2,9,76.7,483.075,4.65,9,16,98.85,0,2,Route: Standard IV Infusion,Target: Clinical setting. MBA: Stable revenue through doctor 'Buy-and-Bill' model.
204,Capecitabine,Lapatinib,359.35,0.4,7,7,121.0,581.1,5.4,2,9,115.0,470.225,2.9,9,16,118.0,0,2,Route: Standard IV Infusion,Target: Clinical setting. MBA: Stable revenue through doctor 'Buy-and-Bill' model.
205,Capecitabine,Palbociclib,359.35,0.4,7,7,121.0,447.5,0.99,2,8,103.0,403.425,0.6950000000000001,9,15,112.0,0,2,Route: Standard IV Infusion,Target: Clinical setting. MBA: Stable revenue through doctor 'Buy-and-Bill' model.
206,Capecitabine,Tucatinib,359.35,0.4,7,7,121.0,480.5,3.62,2,8,111.0,419.925,2.01,9,15,116.0,0,2,Route: Standard IV Infusion,Target: Clinical setting. MBA: Stable revenue through doctor 'Buy-and-Bill' model.
207,Capecitabine,Epirubicin,359.35,0.4,7,7,121.0,543.5,-0.5,6,12,206.0,451.425,-0.04999999999999999,13,19,163.5,2,3,Route: SC / IM Injection,Target: Long-acting release. MBA: Lifecycle management to extend patent life.
208,Capecitabine,Megestrol acetate,359.35,0.4,7,7,121.0,384.5,3.2,0,4,60.4,371.925,1.8,7,11,90.7,3,1,Route: Oral (Pill/Capsule),Target: Home-based care. MBA: High valuation for patient convenience (FDC potential).
209,Capecitabine,Toremifene,359.35,0.4,7,7,121.0,406.0,6.8,0,2,12.5,382.675,3.6,7,9,66.75,3,1,Route: Oral (Pill/Capsule),Target: Home-based care. MBA: High valuation for patient convenience (FDC potential).
210,Capecitabine,Fluoxymesterone,359.35,0.4,7,7,121.0,336.4,2.38,2,4,57.5,347.875,1.39,9,11,89.25,0,2,Route: Standard IV Infusion,Target: Clinical setting. MBA: Stable revenue through doctor 'Buy-and-Bill' model.
211,Capecitabine,Thiotepa,359.35,0.4,7,7,121.0,189.22,0.53,4,3,41.1,274.285,0.465,11,10,81.05,3,1,Route: Oral (Pill/Capsule),Target: Home-based care. MBA: High valuation for patient convenience (FDC potential).
212,Capecitabine,methyltestosterone,359.35,0.4,7,7,121.0,302.5,3.36,1,2,37.3,330.925,1.88,8,9,79.15,3,1,Route: Oral (Pill/Capsule),Target: Home-based care. MBA: High valuation for patient convenience (FDC potential).
213,Capecitabine,Pamidronate,359.35,0.4,7,7,121.0,235.07,-4.7,6,8,161.0,297.21,-2.15,13,15,141.0,0,2,Route: Standard IV Infusion,Target: Clinical setting. MBA: Stable revenue through doctor 'Buy-and-Bill' model.
214,Exemestane,Fulvestrant,296.4,3.7,0,2,34.1,606.8,8.9,2,9,76.7,451.6,6.300000000000001,2,11,55.40000000000001,3,1,Route: Oral (Pill/Capsule),Target: Home-based care. MBA: High valuation for patient convenience (FDC potential).
215,Exemestane,Lapatinib,296.4,3.7,0,2,34.1,581.1,5.4,2,9,115.0,438.75,4.550000000000001,2,11,74.55,3,1,Route: Oral (Pill/Capsule),Target: Home-based care. MBA: High valuation for patient convenience (FDC potential).
216,Exemestane,Palbociclib,296.4,3.7,0,2,34.1,447.5,0.99,2,8,103.0,371.95,2.345,2,10,68.55,3,1,Route: Oral (Pill/Capsule),Target: Home-based care. MBA: High valuation for patient convenience (FDC potential).
217,Exemestane,Tucatinib,296.4,3.7,0,2,34.1,480.5,3.62,2,8,111.0,388.45,3.66,2,10,72.55,3,1,Route: Oral (Pill/Capsule),Target: Home-based care. MBA: High valuation for patient convenience (FDC potential).
218,Exemestane,Epirubicin,296.4,3.7,0,2,34.1,543.5,-0.5,6,12,206.0,419.95,1.6,6,14,120.05,0,2,Route: Standard IV Infusion,Target: Clinical setting. MBA: Stable revenue through doctor 'Buy-and-Bill' model.
219,Exemestane,Megestrol acetate,296.4,3.7,0,2,34.1,384.5,3.2,0,4,60.4,340.45,3.45,0,6,47.25,3,1,Route: Oral (Pill/Capsule),Target: Home-based care. MBA: High valuation for patient convenience (FDC potential).
220,Exemestane,Toremifene,296.4,3.7,0,2,34.1,406.0,6.8,0,2,12.5,351.2,5.25,0,4,23.3,3,1,Route: Oral (Pill/Capsule),Target: Home-based care. MBA: High valuation for patient convenience (FDC potential).
221,Exemestane,Fluoxymesterone,296.4,3.7,0,2,34.1,336.4,2.38,2,4,57.5,316.4,3.04,2,6,45.8,3,1,Route: Oral (Pill/Capsule),Target: Home-based care. MBA: High valuation for patient convenience (FDC potential).
222,Exemestane,Thiotepa,296.4,3.7,0,2,34.1,189.22,0.53,4,3,41.1,242.81,2.115,4,5,37.6,3,1,Route: Oral (Pill/Capsule),Target: Home-based care. MBA: High valuation for patient convenience (FDC potential).
223,Exemestane,methyltestosterone,296.4,3.7,0,2,34.1,302.5,3.36,1,2,37.3,299.45,3.53,1,4,35.7,3,1,Route: Oral (Pill/Capsule),Target: Home-based care. MBA: High valuation for patient convenience (FDC potential).
224,Exemestane,Pamidronate,296.4,3.7,0,2,34.1,235.07,-4.7,6,8,161.0,265.735,-0.5,6,10,97.55,3,1,Route: Oral (Pill/Capsule),Target: Home-based care. MBA: High valuation for patient convenience (FDC potential).
225,Fulvestrant,Lapatinib,606.8,8.9,2,9,76.7,581.1,5.4,2,9,115.0,593.95,7.15,4,18,95.85,0,2,Route: Standard IV Infusion,Target: Clinical setting. MBA: Stable revenue through doctor 'Buy-and-Bill' model.
226,Fulvestrant,Palbociclib,606.8,8.9,2,9,76.7,447.5,0.99,2,8,103.0,527.15,4.945,4,17,89.85,0,2,Route: Standard IV Infusion,Target: Clinical setting. MBA: Stable revenue through doctor 'Buy-and-Bill' model.
227,Fulvestrant,Epirubicin,606.8,8.9,2,9,76.7,543.5,-0.5,6,12,206.0,575.15,4.2,8,21,141.35,2,3,Route: SC / IM Injection,Target: Long-acting release. MBA: Lifecycle management to extend patent life.
228,Fulvestrant,Megestrol acetate,606.8,8.9,2,9,76.7,384.5,3.2,0,4,60.4,495.65,6.050000000000001,2,13,68.55,3,1,Route: Oral (Pill/Capsule),Target: Home-based care. MBA: High valuation for patient convenience (FDC potential).
229,Fulvestrant,Toremifene,606.8,8.9,2,9,76.7,406.0,6.8,0,2,12.5,506.4,7.85,2,11,44.6,3,1,Route: Oral (Pill/Capsule),Target: Home-based care. MBA: High valuation for patient convenience (FDC potential).
230,Fulvestrant,Fluoxymesterone,606.8,8.9,2,9,76.7,336.4,2.38,2,4,57.5,471.6,5.640000000000001,4,13,67.1,3,1,Route: Oral (Pill/Capsule),Target: Home-based care. MBA: High valuation for patient convenience (FDC potential).
231,Fulvestrant,Thiotepa,606.8,8.9,2,9,76.7,189.22,0.53,4,3,41.1,398.01,4.715,6,12,58.90000000000001,3,1,Route: Oral (Pill/Capsule),Target: Home-based care. MBA: High valuation for patient convenience (FDC potential).
232,Fulvestrant,methyltestosterone,606.8,8.9,2,9,76.7,302.5,3.36,1,2,37.3,454.65,6.13,3,11,57.0,3,1,Route: Oral (Pill/Capsule),Target: Home-based care. MBA: High valuation for patient convenience (FDC potential).
233,Fulvestrant,Pamidronate,606.8,8.9,2,9,76.7,235.07,-4.7,6,8,161.0,420.9349999999999,2.1,8,17,118.85,0,2,Route: Standard IV Infusion,Target: Clinical setting. MBA: Stable revenue through doctor 'Buy-and-Bill' model.
234,Lapatinib,Palbociclib,581.1,5.4,2,9,115.0,447.5,0.99,2,8,103.0,514.3,3.195,4,17,109.0,0,2,Route: Standard IV Infusion,Target: Clinical setting. MBA: Stable revenue through doctor 'Buy-and-Bill' model.
235,Lapatinib,Tucatinib,581.1,5.4,2,9,115.0,480.5,3.62,2,8,111.0,530.8,4.51,4,17,113.0,0,2,Route: Standard IV Infusion,Target: Clinical setting. MBA: Stable revenue through doctor 'Buy-and-Bill' model.
236,Lapatinib,Epirubicin,581.1,5.4,2,9,115.0,543.5,-0.5,6,12,206.0,562.3,2.45,8,21,160.5,2,3,Route: SC / IM Injection,Target: Long-acting release. MBA: Lifecycle management to extend patent life.
237,Lapatinib,Megestrol acetate,581.1,5.4,2,9,115.0,384.5,3.2,0,4,60.4,482.8,4.300000000000001,2,13,87.7,3,1,Route: Oral (Pill/Capsule),Target: Home-based care. MBA: High valuation for patient convenience (FDC potential).
238,Lapatinib,Toremifene,581.1,5.4,2,9,115.0,406.0,6.8,0,2,12.5,493.55,6.1,2,11,63.75,3,1,Route: Oral (Pill/Capsule),Target: Home-based care. MBA: High valuation for patient convenience (FDC potential).
239,Lapatinib,Fluoxymesterone,581.1,5.4,2,9,115.0,336.4,2.38,2,4,57.5,458.75,3.89,4,13,86.25,0,2,Route: Standard IV Infusion,Target: Clinical setting. MBA: Stable revenue through doctor 'Buy-and-Bill' model.
240,Lapatinib,Thiotepa,581.1,5.4,2,9,115.0,189.22,0.53,4,3,41.1,385.16,2.965,6,12,78.05,3,1,Route: Oral (Pill/Capsule),Target: Home-based care. MBA: High valuation for patient convenience (FDC potential).
241,Lapatinib,methyltestosterone,581.1,5.4,2,9,115.0,302.5,3.36,1,2,37.3,441.8,4.38,3,11,76.15,3,1,Route: Oral (Pill/Capsule),Target: Home-based care. MBA: High valuation for patient convenience (FDC potential).
242,Lapatinib,Pamidronate,581.1,5.4,2,9,115.0,235.07,-4.7,6,8,161.0,408.085,0.3500000000000001,8,17,138.0,0,2,Route: Standard IV Infusion,Target: Clinical setting. MBA: Stable revenue through doctor 'Buy-and-Bill' model.
243,Palbociclib,Tucatinib,447.5,0.99,2,8,103.0,480.5,3.62,2,8,111.0,464.0,2.305,4,16,107.0,0,2,Route: Standard IV Infusion,Target: Clinical setting. MBA: Stable revenue through doctor 'Buy-and-Bill' model.
244,Palbociclib,Epirubicin,447.5,0.99,2,8,103.0,543.5,-0.5,6,12,206.0,495.5,0.245,8,20,154.5,2,3,Route: SC / IM Injection,Target: Long-acting release. MBA: Lifecycle management to extend patent life.
245,Palbociclib,Megestrol acetate,447.5,0.99,2,8,103.0,384.5,3.2,0,4,60.4,416.0,2.095,2,12,81.7,3,1,Route: Oral (Pill/Capsule),Target: Home-based care. MBA: High valuation for patient convenience (FDC potential).
246,Palbociclib,Toremifene,447.5,0.99,2,8,103.0,406.0,6.8,0,2,12.5,426.75,3.895,2,10,57.75,3,1,Route: Oral (Pill/Capsule),Target: Home-based care. MBA: High valuation for patient convenience (FDC potential).
247,Palbociclib,Fluoxymesterone,447.5,0.99,2,8,103.0,336.4,2.38,2,4,57.5,391.95,1.685,4,12,80.25,3,1,Route: Oral (Pill/Capsule),Target: Home-based care. MBA: High valuation for patient convenience (FDC potential).
248,Palbociclib,Thiotepa,447.5,0.99,2,8,103.0,189.22,0.53,4,3,41.1,318.36,0.76,6,11,72.05,3,1,Route: Oral (Pill/Capsule),Target: Home-based care. MBA: High valuation for patient convenience (FDC potential).
249,Palbociclib,methyltestosterone,447.5,0.99,2,8,103.0,302.5,3.36,1,2,37.3,375.0,2.175,3,10,70.15,3,1,Route: Oral (Pill/Capsule),Target: Home-based care. MBA: High valuation for patient convenience (FDC potential).
250,Palbociclib,Pamidronate,447.5,0.99,2,8,103.0,235.07,-4.7,6,8,161.0,341.285,-1.855,8,16,132.0,0,2,Route: Standard IV Infusion,Target: Clinical setting. MBA: Stable revenue through doctor 'Buy-and-Bill' model.
251,Tucatinib,Epirubicin,480.5,3.62,2,8,111.0,543.5,-0.5,6,12,206.0,512.0,1.56,8,20,158.5,2,3,Route: SC / IM Injection,Target: Long-acting release. MBA: Lifecycle management to extend patent life.
252,Tucatinib,Megestrol acetate,480.5,3.62,2,8,111.0,384.5,3.2,0,4,60.4,432.5,3.41,2,12,85.7,3,1,Route: Oral (Pill/Capsule),Target: Home-based care. MBA: High valuation for patient convenience (FDC potential).
253,Tucatinib,Toremifene,480.5,3.62,2,8,111.0,406.0,6.8,0,2,12.5,443.25,5.21,2,10,61.75,3,1,Route: Oral (Pill/Capsule),Target: Home-based care. MBA: High valuation for patient convenience (FDC potential).
254,Tucatinib,Fluoxymesterone,480.5,3.62,2,8,111.0,336.4,2.38,2,4,57.5,408.45,3.0,4,12,84.25,3,1,Route: Oral (Pill/Capsule),Target: Home-based care. MBA: High valuation for patient convenience (FDC potential).
255,Tucatinib,Thiotepa,480.5,3.62,2,8,111.0,189.22,0.53,4,3,41.1,334.86,2.075,6,11,76.05,3,1,Route: Oral (Pill/Capsule),Target: Home-based care. MBA: High valuation for patient convenience (FDC potential).
256,Tucatinib,methyltestosterone,480.5,3.62,2,8,111.0,302.5,3.36,1,2,37.3,391.5,3.49,3,10,74.15,3,1,Route: Oral (Pill/Capsule),Target: Home-based care. MBA: High valuation for patient convenience (FDC potential).
257,Tucatinib,Pamidronate,480.5,3.62,2,8,111.0,235.07,-4.7,6,8,161.0,357.785,-0.54,8,16,136.0,0,2,Route: Standard IV Infusion,Target: Clinical setting. MBA: Stable revenue through doctor 'Buy-and-Bill' model.
258,Epirubicin,Megestrol acetate,543.5,-0.5,6,12,206.0,384.5,3.2,0,4,60.4,464.0,1.35,6,16,133.2,0,2,Route: Standard IV Infusion,Target: Clinical setting. MBA: Stable revenue through doctor 'Buy-and-Bill' model.
259,Epirubicin,Toremifene,543.5,-0.5,6,12,206.0,406.0,6.8,0,2,12.5,474.75,3.15,6,14,109.25,0,2,Route: Standard IV Infusion,Target: Clinical setting. MBA: Stable revenue through doctor 'Buy-and-Bill' model.
260,Epirubicin,Fluoxymesterone,543.5,-0.5,6,12,206.0,336.4,2.38,2,4,57.5,439.95,0.94,8,16,131.75,0,2,Route: Standard IV Infusion,Target: Clinical setting. MBA: Stable revenue through doctor 'Buy-and-Bill' model.
261,Epirubicin,Thiotepa,543.5,-0.5,6,12,206.0,189.22,0.53,4,3,41.1,366.36,0.01500000000000001,10,15,123.55,0,2,Route: Standard IV Infusion,Target: Clinical setting. MBA: Stable revenue through doctor 'Buy-and-Bill' model.
262,Epirubicin,methyltestosterone,543.5,-0.5,6,12,206.0,302.5,3.36,1,2,37.3,423.0,1.43,7,14,121.65,0,2,Route: Standard IV Infusion,Target: Clinical setting. MBA: Stable revenue through doctor 'Buy-and-Bill' model.
263,Epirubicin,Pamidronate,543.5,-0.5,6,12,206.0,235.07,-4.7,6,8,161.0,389.285,-2.6,12,20,183.5,2,3,Route: SC / IM Injection,Target: Long-acting release. MBA: Lifecycle management to extend patent life.
264,Megestrol acetate,Toremifene,384.5,3.2,0,4,60.4,406.0,6.8,0,2,12.5,395.25,5.0,0,6,36.45,3,1,Route: Oral (Pill/Capsule),Target: Home-based care. MBA: High valuation for patient convenience (FDC potential).
265,Megestrol acetate,Fluoxymesterone,384.5,3.2,0,4,60.4,336.4,2.38,2,4,57.5,360.45,2.79,2,8,58.95,3,1,Route: Oral (Pill/Capsule),Target: Home-based care. MBA: High valuation for patient convenience (FDC potential).
266,Megestrol acetate,Thiotepa,384.5,3.2,0,4,60.4,189.22,0.53,4,3,41.1,286.86,1.865,4,7,50.75,3,1,Route: Oral (Pill/Capsule),Target: Home-based care. MBA: High valuation for patient convenience (FDC potential).
267,Megestrol acetate,methyltestosterone,384.5,3.2,0,4,60.4,302.5,3.36,1,2,37.3,343.5,3.28,1,6,48.84999999999999,3,1,Route: Oral (Pill/Capsule),Target: Home-based care. MBA: High valuation for patient convenience (FDC potential).
268,Megestrol acetate,Pamidronate,384.5,3.2,0,4,60.4,235.07,-4.7,6,8,161.0,309.785,-0.75,6,12,110.7,0,2,Route: Standard IV Infusion,Target: Clinical setting. MBA: Stable revenue through doctor 'Buy-and-Bill' model.
269,Toremifene,Fluoxymesterone,406.0,6.8,0,2,12.5,336.4,2.38,2,4,57.5,371.2,4.59,2,6,35.0,3,1,Route: Oral (Pill/Capsule),Target: Home-based care. MBA: High valuation for patient convenience (FDC potential).
270,Toremifene,Thiotepa,406.0,6.8,0,2,12.5,189.22,0.53,4,3,41.1,297.61,3.665,4,5,26.8,3,1,Route: Oral (Pill/Capsule),Target: Home-based care. MBA: High valuation for patient convenience (FDC potential).
271,Toremifene,methyltestosterone,406.0,6.8,0,2,12.5,302.5,3.36,1,2,37.3,354.25,5.08,1,4,24.9,3,1,Route: Oral (Pill/Capsule),Target: Home-based care. MBA: High valuation for patient convenience (FDC potential).
272,Toremifene,Pamidronate,406.0,6.8,0,2,12.5,235.07,-4.7,6,8,161.0,320.535,1.05,6,10,86.75,3,1,Route: Oral (Pill/Capsule),Target: Home-based care. MBA: High valuation for patient convenience (FDC potential).
273,Fluoxymesterone,Thiotepa,336.4,2.38,2,4,57.5,189.22,0.53,4,3,41.1,262.81,1.455,6,7,49.3,3,1,Route: Oral (Pill/Capsule),Target: Home-based care. MBA: High valuation for patient convenience (FDC potential).
274,Fluoxymesterone,methyltestosterone,336.4,2.38,2,4,57.5,302.5,3.36,1,2,37.3,319.45,2.87,3,6,47.4,3,1,Route: Oral (Pill/Capsule),Target: Home-based care. MBA: High valuation for patient convenience (FDC potential).
275,Fluoxymesterone,Pamidronate,336.4,2.38,2,4,57.5,235.07,-4.7,6,8,161.0,285.735,-1.16,8,12,109.25,0,2,Route: Standard IV Infusion,Target: Clinical setting. MBA: Stable revenue through doctor 'Buy-and-Bill' model.
276,Thiotepa,methyltestosterone,189.22,0.53,4,3,41.1,302.5,3.36,1,2,37.3,245.86,1.945,5,5,39.2,3,1,Route: Oral (Pill/Capsule),Target: Home-based care. MBA: High valuation for patient convenience (FDC potential).
277,Thiotepa,Pamidronate,189.22,0.53,4,3,41.1,235.07,-4.7,6,8,161.0,212.145,-2.085,10,11,101.05,0,2,Route: Standard IV Infusion,Target: Clinical setting. MBA: Stable revenue through doctor 'Buy-and-Bill' model.
278,methyltestosterone,Pamidronate,302.5,3.36,1,2,37.3,235.07,-4.7,6,8,161.0,268.785,-0.6700000000000002,7,10,99.15,3,1,Route: Oral (Pill/Capsule),Target: Home-based care. MBA: High valuation for patient convenience (FDC potential).
